NPM1 and acute myeloid leukemia: To explore if patients have better outcomes when treated at the time of molecular relapse, rather than after overt morphologic relapse, we retrospectively analyzed the outcome of 303 CBF or NPM1-mutated AML patients treated by intensive chemotherapy who had MRD monitoring after having achieved first CR.